Shire sees opportunity

Incoming Shire CEO outlines ophthalmics strategy after SARcode, Premacure deals

With two ophthalmics deals in as many weeks, Shire plc has revealed the next specialty area in which it wants a foothold. The company believes the small size of the ophthalmic practitioner population - about 42,000 in the U.S. - as well as the availability of novel targets, make it a good fit.

The first deal came on March 12 when Shire announced the acquisition of Premacure AB. The Swedish company's Premiplex (formerly iPlex) is in Phase II testing to prevent retinopathy of prematurity (ROP), a rare disease that primarily affects premature infants and can lead to blindness. The protein replacement therapy includes a complex of insulin-like growth factor-1 (IGF-1) and its principal binding protein, IGFBP-3.

Financial details were not disclosed.

Just 13 days later, Shire said it would acquire ophthalmics company SARcode Bioscience Inc. for $160 million up front, plus undisclosed milestones. The deal provides lifitegrast (SAR 1118), an eye drop formulation of a small molecule LFA-1 (CD11a-CD18) antagonist in Phase III testing for dry eye.


Read the full 1647 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers